EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report

被引：13
|
作者：
Zhou, Tong [1 ]
Zhou, Xiaoyue [1 ]
Li, Peng [1 ]
Qi, Chuang [2 ]
Ling, Yang [1 ]
机构：
[1] Soochow Univ, Dept Med Oncol, Changzhou Canc Hosp, 68 Honghe Rd, Changzhou 213032, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai 201100, Peoples R China
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷 / 12期
关键词：
RESISTANCE; CANCER;
D O I：
10.21037/jtd.2018.12.26
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：E802 / E805
页数：4
相关论文
共 50 条
  • [31] EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report
    Pan, Hai
    Zhang, Linlin
    Meng, Fanlu
    Guan, Shasha
    Zhong, Diansheng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [32] Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation
    Tanizaki, Junko
    Banno, Eri
    Togashi, Yosuke
    Hayashi, Hidetoshi
    Sakai, Kazuko
    Takeda, Masayuki
    Kaneda, Hiroyasu
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    LUNG CANCER, 2016, 101 : 11 - 15
  • [33] Acquired multiple EGFR mutations-mediated resistance to a third-generation tyrosine kinase inhibitor in a patient with lung adenocarcinoma who responded to afatinib: A case report and literature review
    Yang, Fang
    Liu, Jingjing
    Xu, Mingming
    Peng, Bin
    ONCOLOGY LETTERS, 2025, 29 (02)
  • [34] Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
    Duan, Hua
    Peng, Yanmei
    Cui, Huijuan
    Qiu, Yuqin
    Li, Qiang
    Zhang, Jingyi
    Shen, Wen
    Sun, Chenyao
    Luo, Chufan
    ONCOTARGETS AND THERAPY, 2018, 11 : 2303 - 2309
  • [35] Surgical treatment of a patient with lung cancer metastasized to the spine with EGFR mutation: A case report
    Aoude, Ahmed Adel
    Amiot, Louis-Philippe
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2012, 3 (10): : 510 - 512
  • [36] A heterochronic genetic change from an EGFR mutation to an ALK rearrangement in a patient with lung adenocarcinoma: a case report
    Shiroyama, Takayuki
    Tamiya, Motohiro
    Hayama, Manabu
    Nishihara, Takashi
    Nishida, Takuji
    Tanaka, Ayako
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Kawahara, Kunimitsu
    Hirashima, Tomonori
    JOURNAL OF THORACIC DISEASE, 2016, 8 (05) : E345 - E348
  • [37] Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review
    Song, Zizheng
    Ren, Guanying
    Wang, Xiaolei
    Du, Haiwei
    Sun, Ying
    Hu, Ling
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (03) : 1126 - 1134
  • [38] Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy
    Zhang, Guoqing
    Yan, Beibei
    Guo, Yanan
    Yang, Hang
    Li, Xiangnan
    Li, Jindong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] Long-term benefit of afatinib combined with bevacizumab in a lung adenocarcinoma patient with a novel rare EGFR Q787L mutation
    Huang, Yingying
    Qin, Shouming
    Tang, Haijuan
    Jiang, Jing
    Liang, Qiuli
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 152
  • [40] LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation
    Hernandez, Marisol Arroyo
    Alatorre, Alexander J.
    Garibay, Julio C.
    Escobar, Jose F.
    Rodriguez, Jeronimo
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345